| Stereochemistry | EPIMERIC |
| Molecular Formula | C21H31NO2 |
| Molecular Weight | 329.4763 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCCOC(=O)C1(C[C@@H]2CC[C@H]1C2)C3=CC=CC=C3
InChI
InChIKey=BDNMABJZSXTKAQ-VCPDFFEISA-N
InChI=1S/C21H31NO2/c1-3-22(4-2)13-8-14-24-20(23)21(18-9-6-5-7-10-18)16-17-11-12-19(21)15-17/h5-7,9-10,17,19H,3-4,8,11-16H2,1-2H3/t17-,19+,21?/m1/s1
| Molecular Formula | C21H31NO2 |
| Molecular Weight | 329.4763 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Bornaptine is a synthetic anticholinergic drug. The compound is a nonselective M1 and M4 antagonist and was shown to inhibit the negative inotropic response to carbachol in the isolated left atrium of the rat with pA2 of 7.27. Bornaprine is used for the treatment of symptoms of Parkinson's disease. A clinical trial showed the superiority of Bornaprine over placebo in reducing parkinsonian tremor. Bornaptine demonstrated positive results in localized hyperhidrosis.
